Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Terminated 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

ALK Positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 21fludarabine 17Specimen Handling 13Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 9Radiotherapy 7Cisplatin 7fludarabine phosphate 5Injections 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Doxorubicin 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3toripalimab 3X-Rays 3Radiosurgery 3Platinum 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × lorlatinib × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡